EU regulators cannot see if women are facing an increased risk of blood clots after shooting AstraZeneca


European drug regulators said Friday that they could not confirm whether AstraZeneca’s COVID-19 vaccine would affect the increased risk of abnormal blood clots associated with low levels of platelets in women and young adults. rice field.

The European Medicines Agency (EMA) statement The European Commission requested us to provide scientific opinion following the first report of thrombosis associated with AstraZeneca’s COVID-19 vaccine, Vaxzevria, associated with thrombocytopenia syndrome (TTS).

“Evidence did not allow the EMA to identify specific risk factors that increase the likelihood of TTS,” drug regulators said.

“Spontaneous reports suggest that the risk is higher in women and young adults and may be lower after the second dose compared to the first dose, but these limits on how data are collected. It means that none of the differences could be confirmed. “

The Commission, which is responsible for elaborating on EMA’s views on all issues related to medicines used by humans, also concluded a further analysis of whether delaying a second dose of Vaxzevria would affect the risk of TTS. rice field.

“There is no evidence that delaying the second dose affects the risk of TTS,” the committee said.

The European Health Organization has repeatedly stated that the second dose can be continued for 4 to 12 weeks after the first dose. He added that it is currently not possible to give definitive recommendations for the use of different vaccines in the second inoculation following the first inoculation in AstraZeneca shots.

According to the EMA, this study contains all available data related to TTS, including a database focused on collecting suspicious side effects for drugs approved in the European Economic Area or being studied in clinical trials. It is based on.

AstraZeneca’s Vaxzevria is a two-shot vaccine developed in collaboration with the University of Oxford.

Drug regulators first began investigating adverse conditions in April after dozens of cases of blood clotting, including deaths, were reported in people after being shot.

Adverse reactions that may be associated with jabs have caused more than 12 countries to suspend the use of AstraZeneca’s COVID-19 vaccine as a precautionary measure, and investigators report blood clots in vaccinated people. I investigated an example.

Reuters contributed to this report.

from NTD News

Lorenz Duchamps